Introduction
============

Lower motor neurons, whose cell bodies are resident in the ventral gray horn of spinal cord, represent the "final common pathway" ([@B53]) through which neuronal activity has to pass in order to generate the contraction of skeletal muscle required for movement. Whilst a large proportion of the synaptic inputs controlling lower motor neuron function arise from descending pathways, including upper motor neurons, pioneering work begun by Sir John Eccles and colleagues in the 1950s has revealed the additional influence of synaptic inputs arising from proprioceptive sensory neurons (including group Ia afferents), whose cell bodies are located in the dorsal root ganglia (DRG) ([@B11]; [@B4]; [@B38]). These sensory inputs have been shown to form monosynaptic connections with lower motor neurons ([Figure 1](#F1){ref-type="fig"}), whereby they can regulate motor neuron firing patterns as part of the monosynaptic spinal stretch reflex arc as well as in other locomotor behaviors ([@B49]).

![Overview of the sensory-motor system and pathologies observed in SMA. Schematic **(A)** and immunohistochemical **(B)** representation of the sensory-motor system, focusing on structures, cell types, and subcellular compartments that have been implicated in SMA pathogenesis. In **(A)**, the text in green indicates the primary pathological changes occurring in specific cell types or in specific subcellular compartments. In **(B)**, immunofluorescence was used to label parvalbumin-expressing cells and projections (proprioceptive neurons; red), neuronal cell bodies (ChAT for motor neurons, beta-III-tubulin for DRG cell bodies; green), and nuclei (DAPI; blue). Note that only a subgroup of DRG cell bodies express parvalbumin and that other markers such as NF200^+^ (mechano- and proprioceptive) and peripherin^+^ (nociceptive) can also be used to identify other types of sensory neurons. Scale bars: 100 μm (spinal cord and DRG); 20 μm (motor neuron). DRG, dorsal root ganglion; ChAT, acetylcholine transferase; DAPI, 4,6-diamidino-2-phenylindole; vGlut1, vesicular glutamate transporter 1; NF200, neurofilament heavy polypeptide (200 kDa).](fnmol-12-00059-g001){#F1}

Recent work has begun to uncover the complex molecular pathways regulating the formation and maintenance of such sensory-motor connectivity in the spinal cord, highlighting key roles for pathways incorporating Sema3e--Plxnd1 signaling ([@B46]) and the RNaseIII protein Dicer ([@B25]). Moreover, several studies have highlighted how disruption of sensory-motor connectivity can result from perturbations in genes and proteins underlying a diverse range of neurodegenerative conditions, including; amyotrophic lateral sclerosis (ALS) ([@B28]), post-polio muscular atrophy (PPMA) ([@B61]), and spinal muscular atrophy (SMA) (see below). In this review we provide an overview of the contributions that sensory-motor connectivity defects make to the pathogenesis of SMA, incorporating new insights into underlying molecular pathways that suggest the existence of common mechanisms across diverse neuromuscular conditions.

Sensory-Motor Defects in Spinal Muscular Atrophy (SMA)
======================================================

SMA is a hereditary form of motor neuron disease, characterized by degeneration and death of lower (alpha) motor neurons in the ventral horn of spinal cord ([@B35]; [@B17]). This leads to progressive proximal muscle weakness, atrophy and, in severe cases, paralysis and death. SMA is caused by homozygous deletion of, or other deleterious variants in, the *SMN1* gene, leading to a significant reduction in the expression of full-length survival motor neuron protein (SMN). SMN is a ubiquitously expressed protein that has been implicated in numerous cellular processes, including snRNP biogenesis, cytoskeletal dynamics, protein homeostasis, and mitochondrial function and is required for cellular survival. A detailed discussion of the cellular roles of SMN can be found in a number of recent review papers \[for example ([@B22]; [@B59]; [@B6])\].

In line with the ubiquitous expression of SMN, SMA is not solely a disease of the lower motor neuron. For example, it is now known that multiple different organ systems and cell types are affected in SMA ([@B44]), including defects in the heart, vasculature and skeletal muscles ([@B18]; [@B52]). Alongside these systemic pathologies, defects in sensory neurons have been reported in SMA patients, including abnormal sensory conduction ([@B9]; [@B64]) or complete absence of sensory nerve action potentials ([@B65]; [@B48]), along with axonal degeneration and loss of myelinated fibers within sensory nerves ([@B31]; [@B45]; [@B51]). Depending on the type of SMA, varying structural abnormalities in muscle spindles have been described, although some of these findings are contradictory and would require further investigation ([@B36]; [@B2]; [@B29]). Several studies conducted on presumed SMA cases (patients diagnosed with SMA before genetic testing was available for the disease) also identified degeneration of sensory nerves, glial bundles within dorsal roots, ballooned neurons and chromatolysis within the DRG ([@B36]; [@B5]; [@B54]; [@B42]). Importantly, reduced synaptophysin expression has been observed adjacent to anterior horn neuron cell bodies in SMA patients, indicating a reduction in the number of or disconnection of afferent nerve fibers, including sensory synapses ([@B24]). Not only do these studies demonstrate defects within the sensory neurons themselves but they also demonstrate the possibility of alterations and lack of connectivity at both extremities of the sensory neuron.

Sensory-Motor Defects in Mouse Models of SMA
--------------------------------------------

The SMA research field has benefited greatly from the availability of a number of animal models that mimic key pathological features of SMA, such as motor neuron death, degeneration of the neuromuscular junction and organ pathology ([@B18]; [@B12]). Indeed, model systems of SMA also recapitulate core defects of the sensory nervous system seen in SMA patients. For example, sensory neurons cultured from a severe mouse model of SMA show defects in neurite outgrowth and growth cone morphology, along with a reduction of beta-actin protein and mRNA in growth cones ([@B27]) -- a phenotype that is similar to that observed in SMN deficient motor neurons ([@B50]). In mouse models of SMA, sensory neurons are smaller, consistent with an appearance of overall reduced size of DRGs ([@B56]). Moreover, the ratio of different subtypes of sensory neurons in SMA DRG is altered (see Section "Molecular Mechanisms Associated With Sensory Neuron Dysfunction in SMA and Related Conditions") ([@B56]). It has also been shown that there is a reduction in myelinated dorsal root axons in SMA mice compared to controls ([@B33]) and a reduction of sensory fibers passing into the ventral horn in SMA mice ([@B39]).

Importantly, in line with what has been observed in SMA patients, these structural defects occurring in sensory neurons have also been associated with defects at the level of synapses formed by sensory neurons in SMA mice ([@B13]). The total number of synapses onto motor neurons in the lumbar region of the spinal cord is significantly reduced in mouse models of SMA ([@B33]). The largest contribution to this overall reduction of sensory synapses comes from a reduction in the number of vGlut1-positive synapses which primarily originate from proprioceptive neurons. This central feature of sensory-motor pathology has now been observed across multiple different SMA mouse models, including the commonly used *Taiwanese* and *delta7* models, suggesting that it is a conserved feature of the disease ([@B33]; [@B39]; [@B56]). Within the lumbar region of spinal cord, the reduction in proprioceptive synapses onto motor neurons is most severe at the level of L1 motor neurons and medial L5 motor neurons ([@B39]). Interestingly, this reduction is observed presymptomatically, ([@B39]; [@B14]) and is associated with significant functional deficits ([@B14]). Thus, sensory-motor connectivity defects reported in SMA mice consistently affect DRGs and motor neurons related to the body regions primarily affected in SMA patients, suggesting that defects occurring in SMA animal models are comparable to sensory-motor pathology observed in patients ([Figure 1](#F1){ref-type="fig"}).

SMN Expression Is Required Throughout the Sensory-Motor System
--------------------------------------------------------------

Whilst motor neuron death is central to the pathogenesis of SMA, in mouse models motor neuron death is preceded by dysfunction of motor neuron and neuromuscular transmission characterized by hyperexcitability, increased input resistance, and decreased synaptic efficacy ([@B33]; [@B39]; [@B14]). These functional defects, in combination with pathological findings that show sensory neuron and synapse loss in SMA patients and mouse models, indicate a complex interplay between the various components of the sensory-motor system eventually leading to motor neuron defects and death.

As loss of SMN expression is central to SMA pathogenesis, recent research has aimed to determine the requirements for SMN expression in the sensory-motor system. In wild-type mice, SMN is expressed throughout all components of the sensory-motor system, including DRGs ([@B56]), muscle, brain and spinal cord ([@B32]; [@B16]), as well as peripheral nerves ([@B23]). In *Drosophila* models of SMA, pan-neuronal restoration of SMN rescues locomotion and motor rhythm phenotypes ([@B26]). In mouse models of SMA, pan-neuronal SMN restoration completely rescues motor neuron numbers and the number of vGlut1^+^ synapses onto motor neurons ([@B32]). To explore this phenomenon further, several research groups have investigated the requirements of SMN expression by restoring SMN in specific cell types of the sensory-motor system, using a range of genetic tools and animal lines ([@B15]; [@B26]; [@B37]; [@B19]; [@B58]; [@B14]). However, it remains difficult to generate a consensus from these studies, meaning that the exact cell-type and temporal requirements for SMN expression in the sensory-motor system remain to be fully determined ([Table 1](#T1){ref-type="table"}). Overall, however, these studies indicate that motor neuron *death* may be primarily due to cell-autonomous effects while the underlying cause of motor neuron *dysfunction* has a larger contribution from defects in proprioceptive neurons which provide a substantial non-cell autonomous component of motor neuron pathology. These findings highlight important issues when considering temporal and tissue specific requirements of SMN-targeted therapies for SMA as restoring SMN expression specifically in proprioceptive and motor neurons at the same time led to the biggest improvement in SMA-associated pathology compared to restoring SMN expression in either motor or proprioceptive neurons alone ([@B14]).

###### 

Overview of studies investigating SMN expression requirements in various components of the sensory-motor system.

  Model system                      Neuron subtype                                          Driver(s)                          Effect of neuron subtype specific SMN restoration on sensory-motor phenotypes              Reference
  --------------------------------- ------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------ -----------
  Mouse (severe)                    Motor neuron                                            Hb9-Cre                            Full rescue of vGlut1^+^ puncta per 100 μm perimeter of motor neuron soma                  [@B15]
                                                                                                                               Complete rescue of cervical, thoracic and lumbar medial motor column motor neuron number   
                                                                                                                                                                                                                          
  Zebrafish                         Motor neuron                                            mnx1/hb9 Cre                       Partial rescue of dorsal root ganglion neuron number                                       [@B19]
  (maternal zygotic *smn* mutant)                                                           Rescue of DRG neuron axon length                                                                                              
                                                                                                                               Complete rescue of motor axon branches total length                                        
                                                                                                                                                                                                                          
  Mouse (delta 7)                   Motor neuron                                            Chat-Cre                           Partial rescue of vGlut1^+^ synapses per motor neuron soma (L1)                            [@B37]
                                                                                                                               Partial rescue of L1 motor neuron number                                                   
                                                                                                                                                                                                                          
  Mouse (delta 7)                   Motor neuron                                            Chat-Cre                           No rescue of vGlut1^+^ synapses onto motor neurons (L2)                                    [@B14]
                                                                                                                               No rescue of motor neuron firing frequency                                                 
                                                                                                                               Partial rescue of L2 motor neuron number                                                   
                                                                                                                                                                                                                          
                                    Proprioceptive neuron                                   Pv-Cre                             Rescue of vGlut1^+^ synapses per motor neuron soma and dendrites (L2)                      
                                                                                                                               Correction of motor neuron firing frequency                                                
                                                                                                                               No rescue of L2 motor neuron number                                                        
                                                                                                                                                                                                                          
  Drosophila (*smn-/-*)             Motor neuron                                            OK371-Gal4; OK6-Gal4               No improvement of defective locomotion velocity, NMJ ePSPs or motor rhythm                 [@B26]
                                                                                                                                                                                                                          
                                    Cholinergic neuron (including proprioceptive neurons)   Cha-Gal4                           Complete rescue of defective locomotion velocity, NMJ ePSPs, and motor rhythm              
                                                                                                                                                                                                                          
  Embryonic stem cell-derived       Motor neuron                                            *Smn* RNAi                         Reduced motor neuron survival                                                              [@B58]
  motor circuit                                                                             *Smn* RNAi^∗^                      No reduction of vGlut2 excitatory synapses onto motor neurons                              
                                                                                                                               No change in motor neuron hyperexcitability                                                
                                                                                                                                                                                                                          
                                    Excitatory interneuron                                  *Smn* RNAi^\#^                     Loss of vGlut2 excitatory synapses onto motor neurons                                      
                                                                                                                               Induced motor neuron hyperexcitability                                                     
                                                                                                                                                                                                                          

ChAT, choline acetyltransferase; Cha, choline acetyltransferase; Pv, Parvalbumin alpha; Hb9/mnx1, Motor neuron and pancreas homeobox protein 1; Smn, survival motor neuron protein; RNAi, RNA interference; L1/2, lumbar segment 1/2; DRG, dorsal root ganglia; NMJ, neuromuscular junction; ePSPs, excitatory postsynaptic potentials.

∗

co-cultured with wild-type excitatory interneurons;

\#

co-cultured with wild-type motor neurons

.

The importance of non-cell autonomous effects on motor neurons is further illustrated by several studies that have investigated the effect of defects intrinsic to specific types of sensory neurons on motor neuron function, in otherwise healthy animals. For example, blocking neurotransmission specifically in proprioceptive neurons in wild-type mice can cause severe motor defects, shortened lifespan and motor neuron dysfunction ([@B14]). Similarly, inhibiting cholinergic neuron activity in *Drosophila* causes reduced locomotion, increased spontaneous rhythmic motor activity and increased EPSPs at the neuromuscular junction by reducing excitatory cholinergic input to motor neurons ([@B26]). Likewise, pharmacological inhibition of excitatory neurotransmission in an embryonic stem cell model of the motor circuit induced motor neuron hyperexcitability but not motor neuron death ([@B58]). Finally, mutations in the mechanosensitive ion channel responsible for mechanosensation of light touch and proprioception, *PIEZO2*, cause a neuromuscular disease characterized by muscle atrophy, aberrant muscle development and function, mild sensory involvement, delayed motor milestones, and scoliosis ([@B7]; [@B8]). Together these studies indicate that defects within sensory neurons themselves can lead to both motor neuron and muscle dysfunction in the absence of defects intrinsic to motor neurons.

In summary, the above work illustrates that SMA mouse models reliably reflect pathological changes in the sensory-motor system of SMA patients. Moreover, it also illustrates the importance of homeostasis of the sensory-motor system: correct functioning of each of its parts is required for it to function correctly as a whole. Mechanistically, these studies have largely focused on motor neuron pathology and SMN requirements. Further molecular studies will be required to better understand the cellular pathways that are involved in regulating these pathological changes. In the next section of this review, we will focus on studies that have aimed to address this issue, also drawing on molecular insights obtained by studying other diseases of the sensory-motor system.

Molecular Mechanisms Underlying Sensory-Motor Connectivity Defects in SMA
=========================================================================

The presence of sensory-motor connectivity defects in SMA (as illustrated by the loss of proprioceptive vGlut1^+^ synapses), alterations in sensory neuron development, and the requirement for SMN expression in different neuronal subpopulations have all been clearly established ([Figure 1](#F1){ref-type="fig"}). In SMA, SMN depletion is at the basis of each of these pathological changes. However, the molecular mechanisms that modulate these changes downstream of SMN depletion are still unclear. It is by further studying the changes downstream of SMN depletion that we will be able to better understand why certain cell types are more sensitive to SMN depletion than others, why defects in certain cellular pathways affect certain cell types more than others, and, ultimately, how SMN depletion leads to SMA, including disruption of sensory-motor connectivity.

Molecular Mechanisms Linked to Motor Neuron Death and Pathology in SMA
----------------------------------------------------------------------

As illustrated by the cell-type specific SMN requirements discussed above, pathways leading to motor neuron death appear to be largely cell autonomous. A better understanding of the molecular mechanisms associated with motor neuron death was gained from studies that compared gene expression profiles of vulnerable and resistant pools of motor neurons. These studies identified differences in basal bioenergetics profiles between vulnerable and resistant motor neuron pools ([@B3]), as well as differences in activation of the cell death-regulating protein p53 and differential regulation of its downstream targets ([@B43]; [@B57]). Mechanistically, it has been shown that the alternative splicing of *Mdm2* and *Mdm4* downstream of and concurrently with disrupted snRNP biogenesis acts synergistically to induce p53 accumulation in SMA ([@B62]). However, despite rescuing the reduction of MN numbers seen in SMA mice, neither the inhibition of p53 signaling nor virus-mediated overexpression of full-length *Mdm2* and *Mdm4* is able to rescue vGlut1^+^-synapse loss ([@B57]; [@B62]).

Other factors have also been linked to motor circuit function in SMA, including stasimon ([@B34]). Decreasing stasimon expression in zebrafish phenocopied motor axon branching defects seen in *smn* morpholino zebrafish, which in turn could be rescued by overexpressing stasimon. Similarly, in a *Drosophila* model of SMA, expressing stasimon in cholinergic (proprioceptive) neurons, but not motor neurons, rescued neurotransmitter release at the NMJ and muscle size defects ([@B34]). All of these studies indicate that, while motor neuron death itself can be rescued by targeting the pathways that directly lead to motor neuron death (such as p53 activation, and Mdm2 and Mdm4 missplicing), this does not rescue motor neuron dysfunction or other motor neuron-associated phenotypes in models of SMA ([@B34]; [@B62]). Other molecular factors such as agrin and plastin3 that are linked to and important for NMJ organization and AMPA receptor functioning have also been implicated in SMA ([@B67]; [@B21]; [@B30]). These factors could be important for the reduced synaptic transmission seen in SMA. Moreover, complement C1q, an important factor in postsynaptic pruning, is upregulated in SMA motor neurons ([@B67]); a event which, along with an increased association of microglia with SMA motor neurons ([@B33]), might contribute to the impaired sensory-motor connectivity observed in SMA.

In summary, the above studies have provided important insights into the molecular mechanisms that underlie motor neuron death in SMA. However, in line with previous pathological and SMN expression studies (see Section "SMN Expression Is Required Throughout the Sensory-Motor System"), these studies also illustrate the importance of non cell-autonomous processes in sensory-motor dysfunction in SMA.

Molecular Mechanisms Associated With Sensory Neuron Dysfunction in SMA and Related Conditions
---------------------------------------------------------------------------------------------

The number of studies investigating the molecular mechanisms that underlie sensory neuron dysfunction in SMA is limited. Therefore, adapting biological findings generated from studies of other, related neuromuscular diseases that are characterized by sensory neuron dysfunction has been of benefit to the SMA research field. For example, Charcot-Marie-Tooth (CMT) disease is a hereditary motor and sensory neuropathy that, depending on its genetic cause, has a variable clinical presentation. CMT type 2D, caused by mutations in the tRNA synthetase *GARS* (glycine tRNA-ligase or GlyRS), has a predominant motor phenotype, although sensory defects are also present ([@B41]). In CMT2D, sensory defects have been shown to be linked to a disruption in sensory neuron fate, downstream of increased expression of mutant GARS ([@B60]). Specifically, when determining sensory neuron subtypes in DRGs from two CMT2D mouse models, fewer large cell body NF200-positive (neurofilament heavy) cell bodies were present in favor of an increased number of peripherin-positive, smaller neurons ([@B60]). Taking this observation into the SMA context provides a possible explanation for the loss of sensory synapses onto lower motor neurons that occurs in the SMA spinal cord, as a shift in sensory neuron cell fate would also lead to changes at the level of their synaptic contacts. Indeed, when investigating sensory neuron development in the *Taiwanese* mouse model of SMA, it was shown that a similar change in sensory neuron fate occurs when SMN expression levels are reduced: a decrease in the number of NF200-positive mechano- and proprioceptive sensory neurons is accompanied by an increase in the number of peripherin-positive nociceptive sensory neurons ([@B56]). Correspondingly, protein levels of GARS were also found to be changed in the spinal cord of SMA mice, as well as in DRGs, in a way that is comparable to changes in GARS observed in mouse models of CMT2D.

The upregulation of GARS in SMA was shown to be regulated by the E1 ubiquitin-activating enzyme, UBA1. UBA1 expression has previously been shown to be significantly decreased in SMA from very early in the pathogenic process and is therapeutically targetable ([@B63]; [@B47]). When investigating protein changes that occur downstream of UBA1, GARS expression was found to depend on UBA1 expression ([@B56]). In line with this, GARS-dependent pathological features of SMA, including altered sensory neuron fate and loss of proprioceptive synapses in the spinal cord, were rescued when UBA1 levels were elevated using a gene therapy approach ([@B56]). These findings provide an interesting pathological link between SMA and CMT2D, but also indicate possible molecular pathways that may underlie sensory-motor pathology in SMA and provide starting points for further research. For example, possible mechanistic links related to disruption of GARS-mediated pathways have been shown to involve dysfunctional Nrp1 / VEGF and Trk signaling ([@B20]; [@B60]). Mutant GARS can aberrantly bind these proteins and this aberrant binding is thought to disrupt their function. However, to what extent these pathways are relevant for sensory defects associated with SMA remains to be determined.

In addition to defects in Trk and Nrp1/VEGF signaling, mutations in GARS are known to lead to increased levels of alpha-tubulin acetylation ([@B10]). Alpha-tubulin acetylation depends on HDAC activity ([@B66]), and, interestingly, both a broad spectrum HDAC inhibitor (trichostatin A) as well as a specific HDAC6 inhibitor (tubastatin A) reversed increases in alpha-tubulin acetylation in a range of cellular and animal models of CMT2D ([@B10]; [@B1]; [@B40]). Intriguingly, the broad spectrum HDAC inhibitor trichostatin A was previously found to rescue vGlut1^+^-synapse loss on spinal motor neurons in the *delta7* model of SMA ([@B39]). To what extent this process is also related to alpha-tubulin acetylation or is due to other effects of HDAC inhibition in SMA remains to be determined. However, this provides an intriguing possible link between HDAC inhibition, GARS function, DRG pathology and sensory synapse loss.

In summary, these findings illustrate how molecular pathways that were previously identified in other disorders, such as CMT2D, can assist discovery of novel mechanisms and therapeutic targets that underlie sensory-motor connectivity defects in SMA.

Concluding Remarks
==================

Motor neurons rely on a range of synaptic inputs, both from within the central nervous system and from sensory neurons projecting from the periphery, to regulate and finetune their activity. In SMA, multiple components of this sensory-motor system have been shown to be disrupted, contributing to motor neuron dysfunction and death. Several molecular pathways have now been identified that regulate sensory neuron dysfunction and these pathways form interesting novel targets for further study and potential therapy development.

The SMA research field is currently at a defining moment. The first disease-modifying therapy for SMA was recently approved, while other therapies are currently in advanced stages of clinical development ([@B55]). However, the fact that current therapies are targeted to the nervous system specifically and do not benefit all patients equally, illustrates that fundamental SMA research is still needed, perhaps more than ever ([@B17]). Furthering our understanding of the molecular mechanisms that underlie pathological changes occurring in specific cell types, such as sensory neurons, will aid the discovery of novel therapeutic strategies. Moreover, this process may be sped up by scrutinizing the existing knowledge from other, related disorders, as is illustrated by the recent identification of shared molecular mechanisms between SMA and CMT2D. Combining advances in these areas of research will be necessary to be able to eventually provide therapies that will benefit and support all SMA patients equally and efficiently.
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